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and not of the stomach and gut, is responsi-
ble for subsequent VAP, Bergmans et al.
[10] confirmed that a reduction in the oro-
tracheal colonization without impact on the
endogenic flora of the stomach and gut 
reduces the incidence of late-onset VAP. In
their study no yeast overgrowth or increase
in fungal infection was observed despite
the absence of an antifungal. VAP preven-
tion by modulating oropharyngal coloniza-
tion and preserving the endogenous gut
flora or minimizing the overgrowth of re-
sistant organisms may impose as a primary
measure in the future [3]. However, this
could be achieved only with a strictly con-
trolled and limited use of parenteral antibi-
otics which has been our strategy over two
decades.
The incidence of late-onset pneumonia
in our study [7] is among the lowest report-
ed in the literature [14], without the use of
any parenteral component. We agree with
van Saene et al. that the addition of intra-
venous antibiotics could have further re-
duced the already low incidence of early-
onset pneumonia, but at the cost of treating
a large number of patients for a marginal
benefit, and the likely risk of resistance ac-
quisition. Assuming that prophylactic in-
travenous antibiotic would halve the inci-
dence of early-onset pneumonia, 34 pa-
tients would need to be treated to prevent
one case.
We agree that, unsurprisingly, the inci-
dence of bacteremia in our study popula-
tion was high due to the choice that we
made to recruit patients at extremely high
risk [7, 15], who represented only 4.2% of
patients admitted in our ICUs over the
study period [7]. Moreover, there was no
expectation that the selective decontamina-
tion regimen used would impact on bacter-
emia rates [7]. Such a high infection rate
cannot be compared with the rates reported
in other SDD studies in which less strin-
gent selection criteria were applied. Re-
garding prevention of bloodstream infec-
tion, we stress again that by far the leading
source of primary infection, including can-
didemia, is vascular devices [16, 17]. Con-
sequently, approaches to prevent gut trans-
location should only be considered in insti-
tutions where effective evidence-based
strategies have been implemented [16].
We were surprised by the superficial
understanding of the process of Candida
infection. Candida infection arises from
endogenous colonization [15]. In all stud-
ies appropriately designed to assess this
process [7, 15, 18, 19, 20], Candida colo-
nization has always preceded infection,
with intensity of colonization being the
prerequisite and the key predisposing fac-
tor for infection [7, 15]. Preventing coloni-
zation surely did contribute to the 90% re-
duction in candidemia incidence [7]. The
high proportion of patients colonized with
Candida certainly does not reflect cross-
transmission but is an expected characteris-
tic of highly selected patients at risk for en-
dogenous colonization, as reported in other
studies that have focused on high-risk pa-
tients only [19, 21, 22, 23, 24].
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Sir: We read with interest the comments of
van Saene et al. Their central argument
concerns selective digestive decontamina-
tion (SDD)—once again. It seems impor-
tant to recall the difference between the
concept of this potentially effective pre-
vention strategy and the so-called “SDD
tetralogy,” referred to by van Saene et al.
The potential benefit of each of the distinct
components of the selective decontamina-
tion approach remains a matter of debate
both in the literature and among experts 
[1, 2, 3]. After almost 20 years of extensive
research, no consensus exists on either the
choice of antibiotics, the route of adminis-
tration, or the necessity to combine intrave-
nous and oral antimicrobials. The reason
why SDD is currently not universally ac-
cepted is not due to its lack of efficacy to
prevent ventilator-associated pneumonia
(VAP) among some patient categories or
even reduce mortality in some conditions,
but because of its parenteral component
and consequent concerns regarding short-
and long-term emergence of antibiotic 
resistance, even following the “princeps”
study [4, 5]. We are completely aware of
the effect of selective decontamination 
given that our group was among the first to
investigate its potential benefit [6], but we
have always used it only in highly selected
patients and without the parenteral compo-
nent [6, 7]. We and others [1, 2, 3, 6, 7, 
8, 9, 10] continue to challenge the overall
appropriateness of the systematic use of in-
travenous antibiotics in ICU patients, used
for as long as 3–5 days in most trials [11].
Such a duration is close to that of VAP
treatment [12]. Let us recall that the “SDD
tetralogy” is based on a nonrandomized tri-
al with an historical control group [4], and
that the impact of the strategy has been
shown to be inversely related to the quality
of the trial [13]. Using a focused hypothesis
that colonization of the oropharynx only,
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